CRH (CRH) H1 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2024 earnings summary
8 Jul, 2026Executive summary
Achieved strong Q2 2024 results with adjusted EBITDA up 12% year-over-year to $2.3bn, margin expansion, and EPS growth of 16%, despite adverse weather and inflationary pressures.
Net income rose 8% year-over-year to $1.3bn on revenues of $9.7bn, reflecting robust operational performance and portfolio management.
Raised full-year guidance for adjusted EBITDA to $6.82–$7.02bn and net income to $3.7–$3.85bn, reflecting robust demand and positive momentum.
$3.7bn invested in M&A YTD, including a majority stake in Adbri (Australia) and key U.S. and European deals.
Ongoing share buybacks ($0.9bn YTD, $1.2bn annualized) and a 5% increase in quarterly dividend to $0.35 per share, demonstrating strong capital returns.
Financial highlights
Q2 2024 revenues were $9.7bn, down 1% year-over-year; H1 2024 revenues reached $16.2bn (flat YoY).
Q2 adjusted EBITDA reached $2.3bn, 12% ahead of prior year, with margin up 270bps to 23.4%; EPS up 16% to $1.89.
Organic EBITDA growth of $222m (11% like-for-like); acquisitions net of divestitures added $15m.
Net debt at end of June was $10.3bn, with net debt/adjusted EBITDA at 1.6x trailing twelve months.
Cash conversion rate consistently over 80% of profits; Q2 2024 cash conversion was 81.2%.
Outlook and guidance
Full-year 2024 adjusted EBITDA guidance raised to $6.82–$7.02bn; net income $3.7–$3.85bn; EPS $5.40–$5.60.
Organic EBITDA growth expected at ~10% at midpoint; acquisitions (notably Adbri) to contribute $150m to EBITDA.
Infrastructure and non-residential demand remain robust; residential new build subdued but long-term fundamentals positive.
Capital expenditure for FY24 guided at $2.2bn–$2.4bn.
Positive pricing momentum expected to continue across markets.
Latest events from CRH
- Strong organic profit growth and cash generation cut year-end net debt below 3x EBITDA.CRH
H2 2015 - Strong growth and cash generation cut leverage to 1.7x while supporting further growth.CRH
H2 2016 - €3.3bn EBITDA, stronger margins and returns, and major acquisitions positioned for further growth.CRH
H2 2017 - U.S. momentum and cost actions supported 2013 progress as net debt fell EUR 519m.CRH
H2 2012 - H2 momentum improved as portfolio actions and disciplined investment set up a moderate 2014 recovery.CRH
H2 2013 - EBITDA rose 11% in 2014; 2015 priorities were growth, integration and debt reduction.CRH
H2 2014 - Sales rose 5% and EBITDA reached €1.66bn as margins proved resilient.CRH
H2 2011 - Cash discipline and cost savings steadied results as markets began to stabilize.CRH
H2 2010 - Q3 EBITDA held near prior year; FY26 guidance is $7.8B–$8.0B amid cost and residential headwinds.CRH
Q3 2026 - Q2 2026 saw strong growth, margin gains, and the Arcosa deal, supporting a positive outlook.CRH
Q2 2026